阿斯利康获中国生物制药实验性COPD药物海外授权AstraZeneca Secures Ex-China License for Sino Biopharmaceutical COPD Drug
中国生物制药公司已与跨国制药巨头阿斯利康正式达成一项药物许可协议。根据双方达成的协议条款，阿斯利康获得了中国生物制药旗下的一款实验性慢性阻塞性肺病（COPD）药物在中国以外地区的独家授权。这意味着阿斯利康将全面负责该实验性呼吸系统治疗药物在中国境外市场的后续开发、临床试验以及商业化推广工作，而中国生物制药则将继续保留该药物在中国国内市场的全部权益。在与阿斯利康达成此项海外许可交易的同时，中国生物制药还宣布深化了与另一家全球领先跨国药企葛兰素史克（GSK）的合作伙伴关系。这两项重要的合作不仅展示了中国生物制药在呼吸系统疾病治疗领域的最新研发进展，也体现了其通过与国际制药巨头合作来加速海外授权和国际化布局的战略。通过与阿斯利康和葛兰素史克建立的紧密合作，中国生物制药能够充分利用这些跨国药企在全球范围内的强大开发实力和商业化网络，共同推动其呼吸系统药物的国际化进程，同时也反映出国际市场对中国本土企业研发的实验性创新疗法的关注。
Sino Biopharmaceutical has struck a drug licensing agreement with AstraZeneca, granting the multinational pharmaceutical company an ex-China license for its experimental Chronic Obstructive Pulmonary Disease (COPD) drug. Under the terms of this newly reached agreement, AstraZeneca secures the rights to develop and commercialize the experimental respiratory treatment in markets outside of China, while Sino Biopharmaceutical retains its rights within the domestic Chinese market. Alongside this licensing transaction with AstraZeneca, Sino Biopharmaceutical has also deepened its partnership with GlaxoSmithKline (GSK). These developments represent an expansion of the Chinese pharmaceutical company's international collaborations with major global drugmakers in the field of respiratory disease treatments. Through these dual arrangements, Sino Biopharmaceutical is cooperating with both AstraZeneca and GSK to advance its respiratory therapies, utilizing the global development and commercialization networks of these multinational partners while continuing its own efforts to bring new treatments to patients. The transactions demonstrate the growing international interest in experimental therapies developed by Chinese biotechnology and pharmaceutical firms.
01阿斯利康获取实验性COPD药物海外授权AstraZeneca Secures Ex-China License for Experimental COPD Drug
根据路透社和《华尔街日报》于2026年7月8日的报道，跨国制药巨头阿斯利康已与中国生物制药正式达成一项药物许可协议。根据该协议条款，阿斯利康获得了中国生物制药旗下的一款实验性慢性阻塞性肺病（COPD）治疗药物在中国以外地区的独家授权。这意味着阿斯利康将全面负责该实验性呼吸系统药物在境外市场的后续开发、临床试验以及商业化推广工作。与此同时，中国生物制药将继续保留该药物在中国国内市场的全部权益。通过该项海外许可交易，阿斯利康能够借助中国生物制药的研发成果拓展其在呼吸系统疾病治疗领域的产品管线，而中国生物制药也将依托阿斯利康在全球范围内的强大开发实力和商业化网络，共同推动该候选药物的国际化进程。
According to reports from Reuters and the Wall Street Journal on July 8, 2026, multinational pharmaceutical company AstraZeneca has secured an exclusive license for an experimental Chronic Obstructive Pulmonary Disease (COPD) drug developed by Sino Biopharmaceutical. Under the terms of this newly reached licensing agreement, AstraZeneca will obtain the rights to develop, manufacture, and commercialize the experimental respiratory treatment in all markets outside of China. Sino Biopharmaceutical, a prominent Chinese pharmaceutical firm, will retain its full rights to the experimental drug within the domestic Chinese market. This strategic licensing transaction allows AstraZeneca to expand its respiratory pipeline by leveraging Sino Biopharmaceutical's research and development achievements, while the Chinese firm utilizes AstraZeneca's extensive global development capabilities and commercialization network to bring the therapeutic candidate to international markets.
02中国生物制药深化与GSK的合作Sino Biopharm Deepens Partnership with GSK
在与阿斯利康达成实验性慢性阻塞性肺病（COPD）药物海外许可协议的同时，中国生物制药也宣布深化了与另一家全球领先跨国药企葛兰素史克（GSK）的合作伙伴关系。根据《华尔街日报》于2026年7月8日的报道，这一举措标志着中国生物制药在呼吸系统疾病治疗领域以及国际化合作方面的进一步拓展。通过与葛兰素史克建立更为紧密的合作关系，中国生物制药旨在借助跨国药企的全球资源和专业优势，共同推进相关药物的开发与市场布局。这一连串的合作动作不仅展示了中国本土医药研发成果在国际市场上的吸引力，也体现了中国生物制药通过多元化国际合作加速其创新疗法走向全球的战略路径。
Alongside the newly reached licensing transaction with AstraZeneca for its experimental Chronic Obstructive Pulmonary Disease (COPD) treatment, Sino Biopharmaceutical has also deepened its strategic partnership with another global pharmaceutical giant, GlaxoSmithKline (GSK). According to reports from the Wall Street Journal on July 8, 2026, this move represents a significant expansion of the Chinese pharmaceutical firm's collaborative network with major multinational drugmakers. By strengthening its relationship with GSK, Sino Biopharmaceutical aims to leverage the global resources, clinical expertise, and commercialization networks of its international partners to advance its therapeutic pipeline. These dual developments highlight Sino Biopharmaceutical's ongoing efforts to accelerate the internationalization of its innovative treatments and demonstrate the growing interest from global pharmaceutical companies in collaborating with Chinese drug developers to address respiratory diseases.
03跨国药企合作的行业背景Context of Multinational Pharmaceutical Collaborations
根据路透社和《华尔街日报》于2026年7月8日的报道，中国生物制药通过与阿斯利康和葛兰素史克（GSK）等全球领先跨国药企的合作，在呼吸系统疾病治疗领域以及国际化授权方面取得了最新进展。这些合作不仅涵盖了实验性慢性阻塞性肺病（COPD）药物在中国以外地区的授权，还深化了与GSK的战略伙伴关系。这些举措体现了中国生物制药在呼吸系统药物研发领域的最新动态，也展示了其通过与跨国制药巨头建立合作关系，共同推动创新疗法在国际市场上的开发与商业化进程。
According to reports from Reuters and the Wall Street Journal on July 8, 2026, Sino Biopharmaceutical's latest developments in respiratory disease treatments and international licensing are highlighted through its collaborations with major multinational pharmaceutical companies, including AstraZeneca and GSK. By securing an ex-China licensing agreement with AstraZeneca for its experimental Chronic Obstructive Pulmonary Disease (COPD) drug and simultaneously deepening its partnership with GSK, the Chinese pharmaceutical firm is actively expanding its global reach. These strategic collaborations reflect the company's ongoing efforts to advance its therapeutic pipeline and leverage the extensive international development and commercialization networks of global industry leaders to bring innovative respiratory treatments to patients worldwide.